Orforglipron Outperforms Oral Semaglutide in Phase 3 ACHIEVE-3 Trial
Eli Lilly's oral orforglipron demonstrated superior HbA1c reduction and weight loss vs oral semaglutide in Phase 3, strengthening the case ahead of an April FDA decision.
Clinical Trials News
276 stories across all digests
Clinical trial coverage on Peptide News Digest pulls in Phase 1 through Phase 3 readouts across the peptide universe — GLP-1 obesity and cardiometabolic trials (SELECT, SURMOUNT-4, ACHIEVE-3, REDEFINE-1, SYNCHRONIZE-1), peptide vaccine work (AMPLIFY-201, MEL39), peptide-drug conjugate trials, and antimicrobial peptide programs.
Most of the noise sits with Lilly and Novo, but the interesting reads are usually elsewhere: Bicycle Therapeutics on solid tumors, Lirum on Ewing sarcoma, Cerapedics on lumbar fusion, Pelage on hair loss. Real-world evidence and registry data also land here when they reframe what the randomized trials showed.
Each entry names the sponsor, the phase, and the endpoint. Browse the latest below, or jump to the readouts by drug at #semaglutide, #tirzepatide, or #orforglipron.
Viking Therapeutics Completes Phase 3 VANQUISH-2 Enrollment for VK2735
Viking enrolled ~1,000 adults in the 78-week trial of VK2735, a GLP-1/GIP dual agonist. Phase 2 showed up to 14.7% body weight reduction in just 13 weeks.
Retatrutide Achieves Record 28.7% Weight Loss in Phase 3 TRIUMPH-4 Trial
Eli Lilly's triple-agonist achieved record weight loss at the highest dose with substantial reductions in knee osteoarthritis pain. Seven more Phase 3 trials expected in 2026.
UBT251 Triple Agonist Delivers 19.7% Weight Loss in Phase 2
Novo Nordisk and United Laboratories' new triple agonist achieved 19.7% weight loss in 24 weeks vs 2.0% placebo, intensifying competition with retatrutide.
TRIUMPH Phase 3 Program Shows Retatrutide Achieves Up to 24% Weight Loss
Analysis of the TRIUMPH program (TRIUMPH-1 through TRIUMPH-4) published in Diabetes, Obesity, and Metabolism shows unprecedented average weight reduction of up to 24% across 5,800+ adults.
Cagrilintide Shows Promising Phase 3 Results as Standalone Obesity Therapy
Phase 3 trial results show cagrilintide, an amylin analogue peptide, achieved significant weight loss as a standalone therapy — a new peptide-based approach distinct from GLP-1 agonists.